EP4139450A1 - Nucleic acid and cell preservative compositions and methods of use - Google Patents
Nucleic acid and cell preservative compositions and methods of useInfo
- Publication number
- EP4139450A1 EP4139450A1 EP21721806.4A EP21721806A EP4139450A1 EP 4139450 A1 EP4139450 A1 EP 4139450A1 EP 21721806 A EP21721806 A EP 21721806A EP 4139450 A1 EP4139450 A1 EP 4139450A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- preservative composition
- biological sample
- composition according
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 260
- 239000003755 preservative agent Substances 0.000 title claims abstract description 163
- 230000002335 preservative effect Effects 0.000 title claims abstract description 163
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 104
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 104
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 104
- 238000000034 method Methods 0.000 title claims abstract description 33
- 239000012472 biological sample Substances 0.000 claims abstract description 150
- 210000004369 blood Anatomy 0.000 claims abstract description 66
- 239000008280 blood Substances 0.000 claims abstract description 66
- 210000004027 cell Anatomy 0.000 claims description 158
- 229920000642 polymer Polymers 0.000 claims description 52
- 239000002357 osmotic agent Substances 0.000 claims description 50
- 239000002532 enzyme inhibitor Substances 0.000 claims description 39
- 239000000523 sample Substances 0.000 claims description 38
- 238000007634 remodeling Methods 0.000 claims description 37
- 239000000084 colloidal system Substances 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 108020004414 DNA Proteins 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 239000003112 inhibitor Substances 0.000 claims description 30
- 230000002503 metabolic effect Effects 0.000 claims description 30
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 25
- 239000003058 plasma substitute Substances 0.000 claims description 23
- 229920001917 Ficoll Polymers 0.000 claims description 22
- 210000001124 body fluid Anatomy 0.000 claims description 22
- 229920001983 poloxamer Polymers 0.000 claims description 22
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 21
- 229960000502 poloxamer Drugs 0.000 claims description 21
- 239000000819 hypertonic solution Substances 0.000 claims description 20
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 claims description 18
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 18
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 18
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- 239000011975 tartaric acid Substances 0.000 claims description 18
- 235000002906 tartaric acid Nutrition 0.000 claims description 18
- 239000000644 isotonic solution Substances 0.000 claims description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 229940021223 hypertonic solution Drugs 0.000 claims description 15
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 12
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 239000003708 ampul Substances 0.000 claims description 12
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 12
- 229920001451 polypropylene glycol Polymers 0.000 claims description 12
- 108010010803 Gelatin Proteins 0.000 claims description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
- 239000003146 anticoagulant agent Substances 0.000 claims description 11
- 229940127219 anticoagulant drug Drugs 0.000 claims description 11
- 229920000159 gelatin Polymers 0.000 claims description 11
- 235000019322 gelatine Nutrition 0.000 claims description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims description 11
- 229910052708 sodium Inorganic materials 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 claims description 10
- 108010088751 Albumins Proteins 0.000 claims description 10
- 102000009027 Albumins Human genes 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 10
- 210000001789 adipocyte Anatomy 0.000 claims description 10
- 210000000601 blood cell Anatomy 0.000 claims description 10
- 210000002449 bone cell Anatomy 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 10
- 210000002889 endothelial cell Anatomy 0.000 claims description 10
- 210000000663 muscle cell Anatomy 0.000 claims description 10
- 210000002569 neuron Anatomy 0.000 claims description 10
- -1 proclin Chemical compound 0.000 claims description 10
- 210000004927 skin cell Anatomy 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 210000000130 stem cell Anatomy 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 108010058846 Ovalbumin Proteins 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 108091092259 cell-free RNA Proteins 0.000 claims description 9
- 108091092356 cellular DNA Proteins 0.000 claims description 9
- 108091092328 cellular RNA Proteins 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 229940092253 ovalbumin Drugs 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 7
- 239000008156 Ringer's lactate solution Substances 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 claims description 7
- 229960003260 chlorhexidine Drugs 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 229910052700 potassium Inorganic materials 0.000 claims description 7
- 239000011591 potassium Substances 0.000 claims description 7
- 239000000600 sorbitol Substances 0.000 claims description 7
- 235000010356 sorbitol Nutrition 0.000 claims description 7
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 7
- 229940033663 thimerosal Drugs 0.000 claims description 7
- 229920003169 water-soluble polymer Polymers 0.000 claims description 7
- 239000005977 Ethylene Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 108010015899 Glycopeptides Proteins 0.000 claims description 6
- 102000002068 Glycopeptides Human genes 0.000 claims description 6
- 108010031792 IGF Type 2 Receptor Proteins 0.000 claims description 6
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- 150000008163 sugars Chemical class 0.000 claims description 6
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 5
- 240000004922 Vigna radiata Species 0.000 claims description 5
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims description 5
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 claims description 5
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 claims description 3
- 230000003161 proteinsynthetic effect Effects 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
- 239000012266 salt solution Substances 0.000 claims 1
- 229920002477 rna polymer Polymers 0.000 description 29
- 102000053602 DNA Human genes 0.000 description 23
- 210000002381 plasma Anatomy 0.000 description 16
- 230000006037 cell lysis Effects 0.000 description 13
- 230000015556 catabolic process Effects 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 239000008187 granular material Substances 0.000 description 7
- 239000008176 lyophilized powder Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 210000004381 amniotic fluid Anatomy 0.000 description 3
- 210000003567 ascitic fluid Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 159000000001 potassium salts Chemical class 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 210000001179 synovial fluid Anatomy 0.000 description 3
- 210000001138 tear Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 108010002885 Polygeline Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 108010033128 Glucan Endo-1,3-beta-D-Glucosidase Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- DQJJMWZRDSGUJP-UHFFFAOYSA-N ethenoxyethene;furan-2,5-dione Chemical compound C=COC=C.O=C1OC(=O)C=C1 DQJJMWZRDSGUJP-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108010026195 glycanase Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 235000010935 mono and diglycerides of fatty acids Nutrition 0.000 description 1
- OKPYIWASQZGASP-UHFFFAOYSA-N n-(2-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CC(O)CNC(=O)C(C)=C OKPYIWASQZGASP-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 229920000765 poly(2-oxazolines) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
Definitions
- the disclosure relates to compositions, methods and kits for preserving nucleic acids and/or cells in blood or other biological samples.
- nucleic acid-based tests are used to analyze variations in the sequence, structure or expression of DNA and RNA for a variety of diagnostic purposes. Indeed, nucleic acids are common examination targets for non-invasive biomedical studies.
- RNA and DNA RNA and DNA
- gene induction and the degradation of gene transcripts begin occurring within minutes of blood or other biological sample collection, making it difficult to accurately analyze the gene expression of the sample at the time it is collected.
- the fresher the blood or other biological sample the better the quality of the nucleic acids of that sample will be. This presents a problem when the nucleic acids of a subject’s blood or biological sample are to be analyzed. It is often the case that blood and other biological samples are collected at a different location and at a very different time than where and when they are analyzed.
- cell lysis In the case of cell free nucleic acids in a blood or other biological sample, the different location and timing of collection and analysis present an additional problem: cell lysis.
- Cell lysis in the collected sample may lead to the contamination of the cell free nucleic acid profile with cellular nucleic acids, making it difficult to accurately analyze the cell free nucleic acids in the blood or biological sample.
- Cell lysis begins to occur soon after blood or other biological samples have been collected. This presents a problem when the samples need to be stored for an extended period of time prior to being analyzed. Thus, there is a further need to preserve blood and other biological samples such that the cell free profile of its nucleic acids is maintained.
- the disclosure is directed to a nucleic acid and cell preservative composition
- a nucleic acid and cell preservative composition comprising: a. one or more osmotic agents, the one or more osmotic agents being present in an amount sufficient to produce a hypertonic or isotonic solution; b. one or more enzyme inhibitors; c. optionally one or more metabolic inhibitors; d. optionally a plasma expander; and e. a Ficoll; wherein the composition does not include glycerol or mannitol.
- the disclosure is directed to a nucleic acid and cell preservative composition
- a nucleic acid and cell preservative composition comprising: a. one or more osmotic agents, the one or more osmotic agents being present in an amount sufficient to produce a hypertonic solution; b. one or more enzyme inhibitors; c. optionally one or more metabolic inhibitors; d. optionally a plasma expander; and e. one or more cell surface remodeling polymers.
- the disclosure is directed to a nucleic acid and cell preservative composition
- a nucleic acid and cell preservative composition comprising: a. optionally one or more osmotic agents; b. one or more enzyme inhibitors; c. optionally one or more metabolic inhibitors; d. optionally a plasma expander; e. optionally one or more cell surface remodeling polymers; f. optionally one or more agents selected from the group consisting of hydroxy ethyl starch, a polymer of N-vinylpyrollidone (NVP), a Ficoll, a protein colloid, a non-protein synthetic colloid, ethylene diol, propylene glycol, a water-soluble polymer and carboxymethylcellulose or a salt thereof; and g.
- NDP N-vinylpyrollidone
- PPG optionally polypropylene glycol
- the disclosure is directed to a combination of a preservative composition of the disclosure and a biological sample.
- the disclosure is directed to a method for preserving nucleic acids and/or cells in a biological sample comprising the steps of combining a preservative composition of the disclosure and the biological sample.
- the disclosure is directed to a kit for preserving nucleic acids and/or cells in a biological sample comprising: a. a preservative composition disclosed herein; and b. optionally, instructions for use of said preservative composition.
- the disclosure is directed to a kit for preserving nucleic acids and/or cells in a biological sample comprising: a. a blood or other biological sample collection tube optionally containing a predetermined amount of an optional anticoagulant; b. a syringe containing a predetermined amount of a preservative composition disclosed herein; and c. optionally, a needle attachable to said syringe.
- the disclosure is directed to a kit for preserving nucleic acids and/or cells in a biological sample
- a blood or other biological sample collection tube optionally containing a predetermined amount of an anticoagulant
- a sealed ampule containing a predetermined amount of a preservative disclosed herein, wherein said ampule comprises a removable closure and wherein said ampule is configured to receive a dispensing means upon removal of the closure by a user.
- the biological sample is derived from a bodily fluid.
- the bodily fluid is blood.
- the nucleic acids are cell free (“cf’) DNA. In other embodiments of the disclosure, the nucleic acids are cellular (i.e., genomic or “g”) DNA.
- the nucleic acids are cell free (“cf’) RNA. In other embodiments of the disclosure, the nucleic acids are cellular (i.e., genomic or “g”) RNA.
- the cells are stem cells, bone cells, blood cells (e.g., red blood cells and/or white blood cells), muscle cells, fat cells, skin cells, nerve cells, endothelial cells, sex cells, pancreatic cells, cancer cells, tumor cells, or circulating tumor cells.
- the cells are lab-derived or modified cells. DESCRIPTION OF THU DISCLOSURE
- osmotic agent refers to an agent that produces a hypertonic or isotonic solution.
- osmotic agents include, but are not limited to, for example, sodium, potassium, magnesium and calcium salts, Ringer’s lactate, Ringer’s acetate, an amino acid, sorbitol, glycerol, mannitol, sugars such as sucrose or glucose, tartaric acid, and glucaric acid, or salts of any of them.
- the one or more osmotic agents serve to alter osmotic pressure in the blood or other biological sample, leading, for example, to the release of water from the cells present in the blood or other biological sample to counteract the imbalance. This can cause, for example, the cells to shrink, thereby, making them more resistant to cell lysis which would otherwise cause the cell-free nucleic acids of the biological sample to be contaminated with cellular nucleic acids, or the cells to be less amenable to assay and analysis. Additionally, it is believed that the optional plasma expander will enhance this effect.
- hypertonic solution refers to a solution with a solute concentration that is higher than physiologic.
- hypertonic solutions include, but are not limited to an about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24% and 25% (by weight) NaCl solution.
- isotonic solution refers to a solution with a solute concentration that is approximately equal to physiologic.
- examples of isotonic solutions include, but are not limited to an about 0.5%, 0.7%, and 1% (by weight) NaCl solution.
- enzyme inhibitor refers to an agent that, alone or in a preservative composition of this disclosure, generates complexes with metal ions, such as calcium, magnesium, manganese or zinc, to reduce blood coagulation, inhibit nucleases and/or reduce enzymatic cell lysis.
- enzyme inhibitors of this disclosure include but are not limited to ethylenediaminetetraacetic acid (EDTA), hydroxyethylethylenediaminetriacetic acid (HEDTA), dithiothreitol (DTT), ethylene glycol- bis(P-aminoethyl ether)-A f ,A f ,A f ',A f '-tetraacetic acid (EGTA), citric acid, oxalate, aurintricarboxylic acid (ATA), tartaric acid, glucaric acid, or salts of any of them, including but not limited to sodium and potassium salts.
- EDTA ethylenediaminetetraacetic acid
- HEDTA hydroxyethylethylenediaminetriacetic acid
- DTT dithiothreitol
- EGTA ethylene glycol- bis(P-aminoethyl ether)-A f ,A f ,A f ',A f
- the inhibition of nucleases will prevent or reduce the degradation of cell-free nucleic acids within the biological sample.
- enzymes that the enzyme inhibitor of this disclosure inhibit include, but are not limited to lysostaphin, zymolase, protease, glycanase, or other enzymes that are known to induce cell lysis, thereby acting to preserve the cells of blood or other biological samples.
- the term “metabolic inhibitor” refers to an agent that, alone or in a preservative composition of this disclosure, inhibits cellular processes, such as cellular respiration, cellular metabolism and metabolic function, thereby reducing the degradation of cell-free nucleic acids.
- the metabolic inhibitor of this disclosure is believed to slow the growth of cells by inhibiting cell metabolic functions and suppressing bacterial growth, thereby reducing degradation of cell-free nucleic acids.
- Examples of metabolic inhibitors of this disclosure include, but are not limited to, sodium azide, thimerosal, proclin, or chlorohexidine.
- plasma expander refers to an agent that produces a hyperoncotic or hypertonic solution.
- plasma expanders include, but are not limited to glycerol, starch, protein colloids (e.g., albumin, ovalbumin, and gelatins) and non protein colloids (e.g., hydroxyethyl starch).
- the optional plasma expanders of the compositions of this disclosure also serve to increase osmotic pressure in the blood plasma or other biological sample, leading to the release of water from the cells to counteract the imbalance. This causes the cells to shrink, thereby, making them more resistant to cell lysis which would otherwise cause the cell-free nucleic acids of the biological sample to be contaminated with cellular nucleic acids, or the cells to be less amenable to assay and analysis.
- cell surface remodeling polymer refers to a polymer that, when present in the amount described in the compositions of this disclosure, interacts with a cell surface (e.g., by binding to a cell surface receptor, or by reacting with specific functional groups on the cell surface) in a blood or other biological sample through covalent interactions, hydrophobic interactions or electrostatic interactions, thereby in some cases causing the cells in the blood or other biological sample to sediment.
- the sedimentation of the cells in the biological sample and/or the interactions of the cell surface and the polymer prevents or reduces cell lysis and the subsequent release of cellular nucleic acids into the sample that may otherwise contaminate, for example, the cell-free nucleic acids or intact cells within the sample.
- the nucleic acids and/or cells can subsequently be isolated and analyzed via conventional methods known in the art.
- cell surface remodeling polymers include, but are not limited to, a copolymer of N-vinylpyrollidone (NVP) and a boronic acid, an arginylglyclaspartic acid (RGD) tripeptide polymer derivative, mung bean phytohaemagglutinin, a poloxamer, and a synthetic glycopeptide that is characterized by one or more ligands for the mannose 6 phosphate receptor (e.g., glycopepties bearing multiple serine-O-mannose-6-phosphonate (M6Pn) residues).
- NDP N-vinylpyrollidone
- RGD arginylglyclaspartic acid
- M6Pn serine-O-mannose-6-phosphonate
- a “Ficoll” refers to a water-soluble high molecular weight sucrose polymer that is formed from the polymerization of sucrose with epichlorohydrin. For example, Ficoll 400 and Ficoll 70.
- a “poloxamer” refers to a water-soluble triblock copolymer having a central hydrophobic chain of polyoxypropylene flanked by two hydrophilic chains of polyoxyethylene.
- Examples of poloxamers include but are not limited to poloxamer pi 88 and poloxamer p407.
- a “protein colloid” refers to a mixture in which one or more proteins is dispersed in solution.
- protein colloids of this disclosure include, but are not limited to albumin, ovalbumin, or gelatins.
- the albumin may be provided as, for example, a human serum albumin (FISA), a bovine serum albumin (BSA) or an ovalbumin.
- BSA bovine serum albumin
- gelatins include, but are not limited, to urea-linked gelatins (e.g., Haemaccel ® ), succinylated gelatins (e.g., Gelofusine ® ), and oxypolygelatins.
- non-protein colloid refers to a mixture in which one or more large molecules or ultramicroscopic particles are dispersed in solution.
- non-protein colloids include, but are not limited to, branched natural polymers of amylopectin, such as hydroxyethylated starches (HES), and polysaccharides, such as dextrans, for example, Dextran 40 and/or Dextran 70.
- a “water-soluble polymer” refers to a polymer that is soluble in aqueous solution.
- water-soluble polymers includes, but are not limited to a polyacrylamide, a polyacrylate, a polydextrose, a polyglycine, a polyethyleneimine, a polylysine, a polyethylene glycol, a polyvinyl pyrrolidone, a polyvinyl alcohol, a polyacrylic acid, a polymer of N-(2-hydroxypropyl) methacrylamide, a polymer of di vinyl ether-maleic anhydride, a polyoxazoline, a polyphosphate, a polyphosphazene, a xanthan gum, a pectin, a chitosan derivative, a dextran, a carrageenan, a guar gum, a cellulose ether, a sodium carboxymethyl cellulose, a hydroxypropyl cellulose, a
- nucleic acid includes both ribonucleic acid (RNA) and deoxyribonucleic acid (DNA).
- RNA and/or DNA may be linear or branched, single or double stranded or fragmented.
- the RNA and DNA may be cellular RNA (i.e., genomic RNA), cellular DNA (i.e., genomic DNA), cell-free RNA, cell-free DNA or combinations thereof. Nucleic acids are found in biological samples, and in particular, blood samples.
- biological sample refers to a sample obtained from a biological source, including lab-derived or lab-modified cells that comprises nucleic acids and/or cells.
- Biological samples may be cell, culture or tissue samples. Additionally, biological samples may be derived from bodily fluids, such as, for example, blood, plasma, serum, urine, saliva, stool, breast milk, tears, sweat, cerebral spinal fluid, synovial fluid, semen, vaginal fluid, ascitic fluid, amniotic fluid, or cell culture media.
- the term “preservative” refers to a composition that is added to a biological sample that inhibits, prevents, or slows the degradation of the nucleic acids and/or cell lysis in that sample.
- the term “treated biological sample” refers to a biological sample that has been combined with a preservative composition as described in this disclosure.
- cells refers to any cell that may be found in blood or other biological samples.
- Types of cells include, but are not limited to stem cells, bone cells, blood cells (e.g., red blood cells or white blood cells), muscle cells, fat cells, skin cells, nerve cells, endothelial cells, sex cells, pancreatic cells, cancer cells, tumor cells, circulating tumor cells (CTCs) and lab derived and/or modified cells.
- compositions of this disclosure are useful in the preservation and stabilization of nucleic acids and/or cells in biological samples.
- the preservative compositions of the disclosure are added to a biological sample containing nucleic acids and/or cells, the degradation of the nucleic acids and/or cell lysis in that sample is reduced, slowed or prevented, as compared to untreated biological samples, allowing for the subsequent isolation and more accurate analysis of the nucleic acids and/or the cells via conventional techniques known in the art, particularly high throughput techniques.
- the preservative compositions of the disclosure inhibit, slow, or reduce cell lysis, allowing the cell free nucleic acids in the sample to remain more consistent in amount and character over prolonged periods of time.
- the reduction of cell lysis in treated biological samples also reduces the release of nucleases, thereby further preventing or reducing degradation of nucleic acids and/or cells within the sample.
- the nucleic acids that can be preserved by the compositions of the disclosure include RNA, DNA or combinations thereof.
- the RNA and DNA can be cellular or cell-free or combinations thereof, i.e., cellular RNA, cellular DNA, cell-free RNA, cell-free DNA, or combinations thereof.
- the DNA and/or RNA is cell-free DNA and/or RNA.
- the cells whose lysis is reduced using the compositions and methods of this disclosure, can be, without limitation, stem cells, bone cells, blood cells, muscle cells, fat cells, skin cells, nerve cells, endothelial cells, sex cells, pancreatic cells, cancer cells, tumor cells, circulating tumor cells and lab-derived or modified cells.
- the disclosure is directed to a nucleic acid and cell preservative composition
- a nucleic acid and cell preservative composition comprising: a. one or more osmotic agents, the one or more osmotic agents being present in an amount sufficient to produce a hypertonic or isotonic solution; b. one or more enzyme inhibitors; c. optionally one or more metabolic inhibitors; d. optionally a plasma expander; and e. a Ficoll; wherein the composition does not comprise glycerol or mannitol.
- the one or more osmotic agent(s) is/are present in the preservative compositions of the disclosure in an amount of about 0.5% to about 20% by weight of the composition. In some embodiments, the osmotic agent is present in an amount of about 1% to about 15%, about 1% to about 20% or about 0.5% to about 10% by weight of the composition.
- the one or more osmotic agent(s) is/are present in an amount sufficient to produce a hypertonic or isotonic solution, including, but not limited to sodium, potassium, magnesium and calcium containing solutions, Ringer’s lactate, Ringer’s acetate, an amino acid, sorbitol, , sugars such as sucrose or glucose, tartaric acid, or glucaric acid or salts of any of them.
- a hypertonic or isotonic solution including, but not limited to sodium, potassium, magnesium and calcium containing solutions, Ringer’s lactate, Ringer’s acetate, an amino acid, sorbitol, , sugars such as sucrose or glucose, tartaric acid, or glucaric acid or salts of any of them.
- the one or more enzyme inhibitor(s) is/are present in the preservative compositions of the disclosure in an amount of about 0.5% to about 30% by weight, in some aspects in an amount of about 0.5% to about 5% by weight and in other aspects from about 1% to about 30% by weight, of the composition.
- the enzyme inhibitor(s) is present in an amount of about 1% to about 20% by weight of the composition. In another embodiment, the enzyme inhibitor is present in an amount of about 1% to about 10% by weight of the composition.
- the one or more enzyme inhibitor(s) is/are ethylenediaminetetraacetic acid (EDTA), hydroxyethylethylenediaminetriacetic acid (HEDTA), dithiothreitol (DTT), ethylene glycol- bis(P-aminoethyl ether)-A f ,A f ,A f ',A f '-tetraacetic acid (EGTA), citric acid, oxalate, aurintricarboxylic acid (ATA), tartaric acid, glucaric acid, or salts of any of them.
- the salts include, but are not limited to, sodium and potassium salts or mixtures thereof.
- the one or more optional metabolic inhibitor(s) is/are present in the preservative compositions of the disclosure in an amount of about 0.01% to about 10% by weight of the composition. In another embodiment, the optional metabolic inhibitor is present in an amount of about 0.01% to about 5% by weight of the composition. In another embodiment, the optional metabolic inhibitor is present in an amount of about 0.01% to about 2% by weight of the composition.
- the one or more optional metabolic inhibitor(s) is/are sodium azide, thimerosal, proclin or chlorohexidine.
- the optional plasma expander is present in the preservative compositions of the disclosure in an amount of about 0.5% to about 40% by weight of the composition, such as about 0.5%, about 1%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35% or about 40% by weight of the composition.
- the optional plasma expander is starch, protein colloids (e.g., albumin, ovalbumin, and gelatins) or non-protein colloids (e.g., hydroxyethyl starch).
- protein colloids e.g., albumin, ovalbumin, and gelatins
- non-protein colloids e.g., hydroxyethyl starch
- a Ficoll serves as a crowding agent, forcing cells out of solution thereby preventing or reducing cell lysis and the subsequent degradation of the cells or release of cellular nucleic acids into the sample that may otherwise contaminate, for example, the cell-free nucleic acids within the sample.
- the nucleic acids and/or cells can subsequently be isolated and more accurately analyzed via conventional methods known in the art.
- the Ficoll is present in an amount of about 10% to about 50% by weight of the composition.
- the one or more agents are present in an amount of about 10% to about 40% by weight, or from about 15% to about 35% by weight, or from about 20% to about 30% by weight of the composition.
- one or more components of the preservative composition of this disclosure may serve the role or function of one or more of the other components of the preservative composition.
- tartaric acid or glucaric acid or a salt thereof may be present in the compositions of the disclosure as an enzyme inhibitor, an osmotic agent, or both.
- the disclosure is directed to a nucleic acid and cell preservative composition
- a nucleic acid and cell preservative composition comprising: a. one or more osmotic agents, the one or more osmotic agents being present in an amount sufficient to produce a hypertonic solution; b. one or more enzyme inhibitors; c. optionally one or more metabolic inhibitors; d. optionally a plasma expander; and e. one or more cell surface remodeling polymers.
- the one or more osmotic agent(s) is/are present in the preservative compositions of the disclosure in an amount of about 1% to about 30% by weight of the composition. In some embodiments, the one or more osmotic agent(s) is/are present in an amount of about 1% to about 20% by weight of the composition. In another embodiment, the one or more osmotic agent(s) is/are present in an amount of about 1% to about 10% by weight of the composition.
- the one or more osmotic agent(s) is/are present in an amount sufficient to produce a hypertonic solution, including, but not limited to sodium, potassium, magnesium and calcium containing solutions, Ringer’s lactate, Ringer’s acetate, an amino acid, sorbitol, sugars such as sucrose or glucose, tartaric acid, or glucaric acid or salts of any of them.
- the one or more enzyme inhibitor(s) is/are present in the preservative compositions of the disclosure in an amount of about 1% to about 30% by weight of the composition.
- the one or more enzyme inhibitor(s) is/are present in an amount of about 1% to about 20% by weight of the composition. In another embodiment, the one or more enzyme inhibitor(s) is/are present in an amount of about 1% to about 10% by weight of the composition.
- the one or more enzyme inhibitor(s) is/are tartaric acid or glucaric acid.
- the one or more optional metabolic inhibitor(s) is/are present in the preservative compositions of the disclosure in an amount of about 0.01% to about 10% by weight of the composition. In another embodiment, the one or more optional metabolic inhibitor(s) is/are present in an amount of about 0.01% to about 5% by weight of the composition. In another embodiment, the one or more optional metabolic inhibitor(s) is/are present in an amount of about 0.01% to about 2% by weight of the composition.
- the one or more optional metabolic inhibitor(s) is/are thimerosal, proclin, or chlorohexidine.
- the optional plasma expander is present in the preservative compositions of the disclosure in an amount of about 1% to about 40% by weight of the composition, such as about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35% or about 40% by weight of the composition.
- the optional plasma expander is a starch, a protein colloid or a non-protein colloid.
- the protein colloid is an albumin, an ovalbumin, or a gelatin.
- the non protein colloid is hydroxyethyl starch.
- the one or more cell surface remodeling polymer(s) is/are present in the compositions of the disclosure in an amount of about 10 and about 50 wt%.
- the one or more cell surface remodeling polymer(s) is/are selected from the group consisting of copolymer of N- vinylpyrollidone (NVP) and a boronic acid, an arginylglyclaspartic acid (RGD) tripeptide polymer derivative, mung bean phytohaemagglutinin, and a synthetic glycopeptide that bears repeated ligands for the mannose 6 phosphate receptor.
- the cell surface remodeling polymer is a poloxamer. In another embodiment, the cell surface remodeling polymer is poloxamer pi 88. In another embodiment, the cell surface remodeling polymer is poloxamer p407.
- one or more components of the preservative composition of this disclosure may serve the role or function of one or more of the components of the preservative composition.
- tartaric acid or glucaric acid or a salt thereof may be present in the compositions of the disclosure as an enzyme inhibitor, an osmotic agent, or both.
- the disclosure is directed to a nucleic acid and cell preservative composition
- a nucleic acid and cell preservative composition comprising: a. optionally one or more osmotic agents; b. one or more enzyme inhibitors; c. optionally one or more metabolic inhibitors; d. optionally a plasma expander; e. optionally one or more cell surface remodeling polymers; f. optionally one or more agentsselected from the group consisting of hydroxy ethyl starch, a polymer of N-vinylpyrollidone (NVP), a Ficoll, a protein colloid, a non-protein synthetic colloid, ethylene diol, propylene glycol, a water-soluble polymer and carboxymethylcellulose or a salt thereof; g.
- NDP N-vinylpyrollidone
- PPG optionally polypropylene glycol
- PPG optionally polypropylene glycol
- at least one cell surface remodeling polymer (e) or agent (f) is present, provided that when a cell surface remodeling polymer (e) is not present, the one or more optional osmotic agents, if present, is/are present in an amount of about 0.1% to about 1% by weight of the composition, that amount being sufficient to produce an isotonic or hypertonic solution and further provided that when an agent (f) is not present, the one or more optional osmotic agents, if present, is/are present in an amount sufficient to produce an isotonic solution or is/are about 0.1% to about 1% by weight of the composition, that amount being sufficient to produce an isotonic or hypertonic solution.
- PPG polypropylene glycol
- the one or more optional osmotic agent(s) is/are present in the preservative compositions of the disclosure in an amount of about 0.1% to about 30% by weight of the composition. In some embodiments, the osmotic agent is present in an amount of about 0.1% to about 10%, about 1% to about 15%, about 1% to about 20% by weight of the composition. In some embodiments, the osmotic agent is present in an amount of about 0.1% to about 1% by weight of the composition. In some embodiments, no osmotic agent is present.
- the one or more optional osmotic agent(s) is/are present in an amount sufficient to produce an isotonic or hypertonic solution, as recited, including, but are not limited to, sodium, potassium, magnesium and calcium containing solutions, Ringer’s lactate, Ringer’s acetate, an amino acid, sorbitol, mannitol, sugars such as sucrose or glucose, tartaric acid, glucaric acid, or salts of any of them.
- the one or more enzyme inhibitor(s) is/are present in the preservative compositions of the disclosure in an amount of about 0.5% to about 30% by weight, in some aspects in an amount of about 0.5% to about 5% by weight and in other aspects from about 1% to about 30% by weight of the composition. In some embodiments, the enzyme inhibitor(s) is/are present in an amount of about 1% to about 20% by weight of the composition. In another embodiment, the enzyme inhibitor(s) is/are present in an amount of about 1% to about 10% by weight of the composition.
- the one or more enzyme inhibitor(s) is/are ethylenediaminetetraacetic acid (EDTA), hydroxyethylethylenediaminetriacetic acid (HEDTA), dithiothreitol (DTT), ethylene glycol- bis(P-aminoethyl ether)-A f ,A f ,A f ',A f '-tetraacetic acid (EGTA), citric acid, oxalate, aurintricarboxylic acid (ATA), tartaric acid, glucaric acid, or salts of any of them.
- the salts include, but are not limited to, sodium and potassium salts or mixtures thereof.
- the one or more enzyme inhibitor is ethylenediaminetetraacetic acid (EDTA) and salts thereof.
- the one or more optional metabolic inhibitor(s) is/are present in the preservative compositions of the disclosure in an amount of about 0.01% to about 10% by weight of the composition. In another embodiment, the optional metabolic inhibitor(s) is/are present in an amount of about 0.01% to about 5% by weight of the composition. In another embodiment, the optional metabolic inhibitor(s) is/are present in an amount of about 0.01% to about 2% by weight of the composition.
- the one or more optional metabolic inhibitor(s) is/are sodium azide, thimerosal, proclin or chlorohexidine.
- the optional plasma expander is present in the preservative compositions of the disclosure in an amount of about 0.5% to about 40% by weight of the composition, such as about 0.5%, about 1%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, or about 40% by weight of the composition.
- the optional plasma expander is glycerol, a starch, a protein colloid (e.g., albumin, ovalbumin, and gelatins) or a non-protein colloid (e.g., hydroxyethyl starch).
- the protein colloid is an albumin, an ovalbumin, or a gelatin.
- the non-protein colloid is hydroxyethyl starch.
- the one or more optional cell surface remodeling polymer(s) is/are present in the compositions of the disclosure in an amount of about 10 and about 50 wt%.
- the one or more optional cell surface remodeling polymer(s) is/are present in an amount of about 10% to about 40% by weight, or from about 15% to about 35% by weight, or from about 20% to about 30% by weight of the composition.
- the one or more cell surface remodeling polymer(s) is/are selected from the group consisting of copolymer of N- vinylpyrollidone (NVP) and a boronic acid, an arginylglyclaspartic acid (RGD) tripeptide polymer derivative, mung bean phytohaemagglutinin, and a synthetic glycopeptide that bears repeated ligands for the mannose 6 phosphate receptor.
- NRP N- vinylpyrollidone
- RGD arginylglyclaspartic acid
- the cell surface remodeling polymer is a poloxamer or other amphiphilic compounds that act as surfactants for the cells in blood or other biological samples.
- the cell surface remodeling polymer is poloxamer pl88.
- the cell surface remodeling polymer is poloxamer p407.
- the one or more optional agent(s) is/are present in an amount of about 1% to about 50% by weight of the composition.
- the one or more optional agent(s) is/are present in an amount of about 1% to about 40% by weight, or from about 15% to about 35% by weight, or from about 20% to about 30% by weight of the composition.
- the one or more optional agent(s) is/are hydroxyethyl starch. In some embodiments of the third aspect of the disclosure, the one or more optional agent(s) is/are a Ficoll. In some embodiments, the Ficoll is Ficoll 400. In some embodiments of the third aspect of the disclosure, the one or more optional agent(s) is/are a protein colloid. In some embodiments, the one or more optional agent(s) is/are a non-protein colloid. In some embodiments, the one or more optional agent(s) is/are a water-soluble polymer.
- one or more cell surface remodeling polymer(s) is/are present and no agent(s) is/are present.
- one or more agent(s) is/are present and no cell surface remodeling polymer(s) is/are present.
- one or more agent(s) is/are present and one or more cell surface remodeling polymer(s) is/are also present.
- the optional polypropylene glycol (PPG) is present in an amount of about 0.1 to 10% by weight of the composition.
- the optional PPG is present in an amount of about 5% to about 10% by weight, or from about 1% to about 5% by weight, or from about 0.1% to about 1% by weight of the composition.
- one or more components of the preservative composition of this disclosure may serve the role or function of one or more of the components of the preservative composition.
- tartaric acid or glucaric acid or a salt thereof may be present in the compositions of the disclosure as an enzyme inhibitor, an osmotic agent, or both.
- human serum albumin may be present in the compositions of the disclosure as a one or more agent, an optional plasma expander, or both.
- the preservative compositions according to the disclosure can be in the form of a lyophilized powder, granules, tablets, or as a solution (e.g., wherein the preservative composition is reconstituted in a suitable vehicle).
- the lyophilized powder, granules and/or tablets may be added directly to the biological sample or may be reconstituted prior to being added to a biological sample.
- the lyophilized powder, granules, and/or tablets may, for example, be reconstituted by dissolving the composition in a suitable vehicle.
- suitable vehicles include but are not limited to water, saline, Ringer’s solution, fixed oils of vegetable origin, mono and diglycerides of fatty acids, ethanol, glycerin, propylene glycol, and an optional plasma expander of this disclosure.
- the biological sample may be added to the lyophilized powder, granules, tablets or the reconstituted composition (i.e., solution) directly.
- the bodily fluid can serve as an acceptable vehicle for solubilizing the preservative composition.
- the lyophilized powder, granule, and/or tablet form of the preservative composition can be combined with the bodily fluid, thereby being solubilized by the bodily fluid.
- the collection tube or container contains the preservative composition as a lyophilized powder, granule, tablet or solution before the biological sample is collected in the tube or container.
- the preservative composition of the disclosure is in the form of an aqueous solution.
- the aqueous solution may be combined with a biological sample or the biological sample combined with the aqueous solution.
- the disclosure is directed to a combination of a preservative composition of the disclosure and a biological sample.
- the disclosure is directed to a method for preserving nucleic acids and/or cells in a biological sample comprising the steps of combining a preservative composition of this disclosure and the biological sample.
- the biological sample is a cell or tissue sample.
- the biological sample is derived from bodily fluids.
- the bodily fluid is blood, plasma, serum, urine, saliva, stool, breast milk, tears, sweat, cerebral spinal fluid, synovial fluid, semen, vaginal fluid, ascitic fluid, or amniotic fluid.
- the biological fluid is blood, e.g., whole blood or fractions thereof.
- the biological sample may include cells or may be cell-free.
- the biological sample comprises stem cells, bone cells, blood cells, muscle cells, fat cells, skin cells, nerve cells, endothelial cells, sex cells, pancreatic cells, cancer cells, tumor cells, or circulating tumor cells.
- the biological sample comprises a nucleic acid selected from RNA, DNA, or a combination thereof.
- the nucleic acid is cell-free RNA, cell-free DNA, or a combination thereof.
- the nucleic acid is cellular RNA, cellular DNA, or a combination thereof.
- the biological sample can be combined with the preservative composition of the disclosure in a number of ways.
- the biological sample can be collected into a suitable container followed by the addition of the preservative composition to that container, e.g., by syringe or pipette.
- the preservative composition can alternatively be added to a suitable container for biological sample collection prior to the collection of the biological sample.
- the preservative composition is added to a biological sample.
- the biological sample is added to the preservative composition.
- the disclosure also contemplates methods wherein the components of the preservative composition are added to the biological sample simultaneously or separately.
- this disclosure is directed to methods of preserving nucleic acids and/or cells in a biological sample comprising contacting a biological sample with, in any order or simultaneously, the constituent components of the preservative composition of the disclosure.
- a suitable container for the collection of the biological sample already contains one or more of the components of the preservative composition, and the remaining components are added to the biological sample, either sequentially, or simultaneously, with the biological sample being collected.
- a blood collection tube already containing a suitable enzyme inhibitor e.g., tartaric acid, or EDTA or its salts, or glucaric acid
- a suitable enzyme inhibitor e.g., tartaric acid, or EDTA or its salts, or glucaric acid
- the remaining components i.e., the osmotic agent, optionally one or more of a metabolic inhibitor, an optional plasma expander, and the one or more agents
- the components of the preservative composition are added to the biological sample, either sequentially, or simultaneously, after the biological sample has been collected.
- all of the required components of the preservative composition, and optionally the optional components are present in the container before the container is used to collect the sample.
- the container to be used for sample collection contains the preservative composition in a lyophilized powder form. In some embodiments, the container to be used for sample collection contains the preservative composition in a granulate form. In some embodiments, the container to be used for sample collection contains the preservative composition in tablet form. In some embodiments, the container to be used for sample collection contains the preservative composition and a suitable vehicle. In some embodiments, the container to be used for sample collection contains the preservative composition as an aqueous solution. In another embodiment, the container to be used is for blood sample collection further comprises an anticoagulant.
- anticoagulants include but are not limited to EDTA (which may also function as an enzyme inhibitor), sodium citrate, citrate-theophylline-adenosine-dipyridamole (CTAD), lithium heparin, sodium heparin, sodium fluoride, acid-citrate-dextrode (ACD), and sodium polyanethol sulfonate.
- CTAD citrate-theophylline-adenosine-dipyridamole
- ACD acid-citrate-dextrode
- sodium polyanethol sulfonate examples include but are not limited to EDTA (which may also function as an enzyme inhibitor), sodium citrate, citrate-theophylline-adenosine-dipyridamole (CTAD), lithium heparin, sodium heparin, sodium fluoride, acid-citrate-dextrode (ACD), and sodium polyanethol sulfonate.
- the suitable container is an evacuated blood sample collection tube.
- the amount of the preservative composition that may be combined with a biological sample can be determined by those skilled in the art through routine experimentation.
- the ratio of the preservative composition to the biological sample may be from about 1 : 10 to about 1 : 1 v/v. In some embodiments, the ratio of the preservative composition to the biological sample is from about 1 :8 to about 1 :2 v/v. In some embodiments, the ratio of the preservative composition to the biological sample is from about 1 :6 to about 1 :3 v/v. In some embodiments, the ratio of the preservative composition to the biological sample is from about 1:5 to about 1:4 v/v.
- the nucleic acids and/or cells may be isolated from the biological sample for analysis using methods known to those skilled in the art including extraction, centrifugation and chromatography methods. Those skilled in the art will recognize that there are many methods that can be used to isolate the nucleic acids and/or cells from a biological sample.
- Nucleic acids and/or cells that are preserved using the preservative composition of this disclosure can be isolated from treated biological samples after extended periods of storage under a variety of temperature conditions.
- the biological sample that has been contacted with the preservative composition of this disclosure can be stored, either under ambient conditions, or low temperature for at least 1 day, at least 1 week, at least 2 weeks, at least 3 weeks or at least 4 weeks.
- the compositions of the disclosure allow for the preservation of a biological sample (i.e., nucleic acids and/or cells in the biological sample) for extended periods of time at a temperature ranging from about -20 °C to about 30 °C.
- the preservative composition is capable of preserving a biological sample (i.e., nucleic acids and/or cells in the biological sample) for at least 1 week, at least 2 weeks, at least 3 weeks or at least 4 weeks at ambient temperature. In some embodiments the preservative composition is capable of preserving a biological sample for at least 2 weeks at ambient temperature. In some embodiments, the preservative composition of the disclosure is capable of preserving a biological sample (i.e., nucleic acids and/or cells in the biological sample) for at least 1 week, at least 2 weeks, at least 3 weeks or at least 4 weeks at 4°C.
- the preservative composition of the disclosure is capable of preserving a biological sample (i.e., nucleic acids and/or cells in the biological sample) for at least 1 week, at least 2 weeks, at least 3 weeks or at least 4 weeks at -20°C.
- Nucleic acids (RNA and DNA) that are preserved using the compositions and methods of this disclosure display good yields, purity, integrity and for the RNA amplifiability.
- the preservative compositions according to the disclosure may be provided as part of a kit that is to be received by the user.
- the kit allows the preservative composition(s) of this disclosure to be readily combined with a biological sample such that the nucleic acids and/or the cells present in that biological sample are preserved for an extended period of time, e.g., at least 1 week, at least 2 weeks, at least 3 weeks or at least 4 weeks.
- the preservative composition can be provided such that it is combined with a biological sample after that biological sample has been collected. Alternatively, the preservative composition is provided such that it is combined with the biological sample at the time the biological sample is collected.
- the preservative composition is provided as an aqueous solution in a dispensing means.
- the dispensing means is a syringe.
- the amount of preservative in the dispensing means may be a predetermined amount such that the ratio of the preservative composition that is combined with the biological sample is capable of preserving the nucleic acids and/or cells of that sample over an extended period of time.
- the kit may further comprise a needle attachable to said syringe.
- the kit is for preserving nucleic acids and/or cells in a blood sample, and further comprises a blood collection tube optionally containing a predetermined amount of an anticoagulant.
- the preservative composition is provided in a sealed ampule, wherein said ampule comprises a removable closure, and wherein said ampule is configured to receive a dispensing means upon removal of the closure by the user.
- the dispensing means is a pipette or a syringe.
- the kit is for preserving nucleic acids and/or cells in a blood sample and further comprises a blood collection tube containing a predetermined amount of an anticoagulant.
- the kit is directed to preserving nucleic acids and/or cells in a blood sample and comprising a blood collection tube, optionally containing a predetermined amount of an anticoagulant, and a preservative composition of this disclosure.
- the disclosure is directed to a kit for preserving nucleic acids and/or cells in a biological sample comprising: a. a preservative composition disclosed herein; and b. optionally, instructions for use of said preservative composition.
- the disclosure is directed to a kit for preserving nucleic acids and/or cells in a biological sample comprising: a. a blood or other biological sample collection tube optionally containing a predetermined amount of an optional anticoagulant; b. a syringe containing a predetermined amount of a preservative composition disclosed herein; and c. optionally, a needle attachable to said syringe.
- the disclosure is directed to a kit for preserving nucleic acids and/or cells in a biological sample
- a blood or other biological sample collection tube optionally containing a predetermined amount of an anticoagulant; and b. a sealed ampule, containing a predetermined amount of a preservative disclosed herein, wherein said ampule comprises a removable closure and wherein said ampule is configured to receive a dispensing means upon removal of the closure by a user.
- the biological sample is a cell or tissue sample.
- the biological sample is derived from a bodily fluid.
- the bodily fluid is blood, plasma, serum, urine, saliva, stool, breast milk, tears, sweat, cerebral spinal fluid, synovial fluid, semen, vaginal fluid, ascitic fluid, or amniotic fluid.
- the bodily fluid is whole blood or fractions thereof.
- the biological sample may include cells or may be cell-free.
- the biological sample comprises stem cells, bone cells, blood cells, muscle cells, fat cells, skin cells, nerve cells, endothelial cells, sex cells, pancreatic cells, cancer cells, tumor cells, circulating tumor cells, or a combination thereof.
- the biological sample comprises a nucleic acid selected from RNA, DNA, or a combination thereof.
- the nucleic acid is cell-free RNA, cell-free DNA, or a combination thereof.
- the nucleic acid is cellular RNA, cellular DNA, or a combination thereof.
- Composition 1 2.86% by weight NaCl (osmotic agent), 0.02% by weight NalN (metabolic inhibitor), 0.75% by weight 2Na-EDTA and 0.75% by weight 4Na-EDTA (enzyme inhibitors), 20.0% by weight Ficoll PM400 (agent), and the balance water.
- Composition 2 2.86% by weight NaCl (osmotic agent), 0.02% by weight NalN (metabolic inhibitor), 0.75% by weight 2Na-EDTA and 0.75% by weight 4Na-EDTA (enzyme inhibitors), 20.0% by weight poloxamer pi 88 (cell surface remodeling polymer), and the balance water.
- Blood samples from various donors are collected into blood sample collection tubes to assess the plasma volume of samples treated with a preservative composition according to this disclosure.
- the preservative compositions of Example 1 are tested by adding the blood sample into a tube containing 2 mL of the preservative composition.
- the combined preservative composition and blood sample is then centrifuged for ⁇ 15 minutes at room temperature and 425 g, resulting in the formation of a pellet in the collection tube.
- the upper plasma layer (supernatant) is transferred to a separate collection tube using a pipette.
- the transferred supernatant is then centrifuged again for ⁇ 15 minutes at 4°C and at 16,000 g to remove any inadvertently transferred cell debris or precipitate and the volume of residual plasma is measured.
- the measured volume is referred to herein as the “plasma volume”.
- the “plasma volume” is expected to be an important factor in facilitating the use of the aspects of the present disclosure in high- throughput applications.
- the use of automation and robotics in those applications necessitates consistent plasma volumes, ideally between 3-6 mL.
- the “plasma volume” of mixtures that were processed according to the above procedure and preserved in tubes containing composition 1 were observed to be 6-6.2 mL.
- the “plasma volume” of mixtures that were processed according to the present procedure and preserved in tubes containing composition 2 were observed to be 2.2-3.7 mL.
- Example 3 Analysis of the Integrity of the Isolated cfDNA and RNA [0123] Blood samples from various donors are collected into the blood sample collection tubes to assess the ability of embodiments of the preservative compositions of this disclosure to preserve cfDNA and RNA.
- the preservative compositions of Example 1 are tested by adding the blood sample into a tube containing 2 mL of the preservative composition.
- cfDNA and RNA are isolated from the samples using extraction and separation techniques known in the art.
- One such cfDNA extraction method involves using a MagMAXTM Cell-Free DNA Isolation Kit.
- One such RNA extraction method involves using a procedure based on Beckman Coulter’s RNAdvance Blood Kit.
- the integrity of the cfDNA is analyzed by qPCR of long and short DNA fragments and characterized by the ratio of long fragment over short fragment (222bp/90bp). The obtained ratio is referred to herein as the DNA Integrity Number (DIN).
- DIN is an objective metric of cfDNA quality When the DIN is ⁇ 0.5, the cfDNA is considered to be pure (i.e., the plasma is not contaminated by gDNA (cellular or genomic DNA)).
- a 10-fold dilution series of the gDNA (lng/pL to O.Olng/ pL) is prepared for a standard curve.
- a forward and reverse primer mix is prepared at 5mM concentration by mixing 5pL of 100 mM forward primer, 5pL of 100 mM reverse primer with 90 pL of nuclease-free water.
- RNA integrity number is an objective metric of total RNA quality ranging from 10 (highly intact RNA) to 1 (completely degraded RNA).
- composition 1 or 2 The integrity of cfDNA extracted from blood samples (i.e., the DIN) that are preserved in tubes containing either composition 1 or 2 is generally high, as the ratio of long fragment over short fragment (222bp/90bp) from the qPCR assay is observed to be in a range of ⁇ 0.1 to 0.7.
- the RIN of the RNA isolated from blood samples that are preserved in tubes containing either composition 1 or 2 is generally high, as they were observed to have a RIN in a range of 7.4 to 9.1.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063012637P | 2020-04-20 | 2020-04-20 | |
PCT/US2021/012844 WO2021142375A1 (en) | 2020-01-10 | 2021-01-08 | Nucleic acid and cell preservative compositions and methods of use |
PCT/US2021/027573 WO2021216353A1 (en) | 2020-04-20 | 2021-04-15 | Nucleic acid and cell preservative compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4139450A1 true EP4139450A1 (en) | 2023-03-01 |
Family
ID=78271032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21721806.4A Pending EP4139450A1 (en) | 2020-04-20 | 2021-04-15 | Nucleic acid and cell preservative compositions and methods of use |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4139450A1 (en) |
JP (1) | JP2023524649A (en) |
CN (1) | CN115943208A (en) |
CA (1) | CA3176189A1 (en) |
WO (1) | WO2021216353A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3225810A1 (en) * | 2021-07-15 | 2023-01-19 | Joseph Piccirilli | Preservative composition for nucleic acids and biological samples and methods of use |
WO2024054494A1 (en) * | 2022-09-06 | 2024-03-14 | Sio2 Medical Products, Inc. | Preservative composition for biological markers and biological samples and methods of use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7029840B2 (en) * | 2000-11-15 | 2006-04-18 | Becton, Dickinson And Company | Method for preservation of cells and nucleic acid targets |
CA2868805C (en) * | 2012-03-28 | 2018-09-04 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for the collection and isolation of nucleic acids from biological specimens |
CN105158455B (en) * | 2015-09-17 | 2018-10-16 | 深圳市钠科生物有限公司 | A kind of biological sample collection method, apparatus, system, biological sample stable reagent and application improving sample detection precision and accuracy |
-
2021
- 2021-04-15 CA CA3176189A patent/CA3176189A1/en active Pending
- 2021-04-15 WO PCT/US2021/027573 patent/WO2021216353A1/en unknown
- 2021-04-15 CN CN202180043853.1A patent/CN115943208A/en active Pending
- 2021-04-15 JP JP2022564084A patent/JP2023524649A/en active Pending
- 2021-04-15 EP EP21721806.4A patent/EP4139450A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115943208A (en) | 2023-04-07 |
CA3176189A1 (en) | 2021-10-28 |
JP2023524649A (en) | 2023-06-13 |
WO2021216353A1 (en) | 2021-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7166169B2 (en) | Method for preparing a sterile composition for sterilization of extracellular nucleic acids | |
JP6608280B2 (en) | Biological sample stabilization | |
JP6664332B2 (en) | Stabilization and isolation of extracellular nucleic acids | |
US11767522B2 (en) | Preservation of cell-free nucleic acids in biological samples | |
EP4139450A1 (en) | Nucleic acid and cell preservative compositions and methods of use | |
CN107083382B (en) | A kind of blood preseration agent and its application for protecting dissociative DNA | |
EP4087926A1 (en) | Nucleic acid and cell preservative compositions and methods of use | |
EP4116401A1 (en) | Storage container for cell-containing solution and storage solution | |
WO2023288115A1 (en) | Preservative composition for nucleic acids and biological samples and methods of use | |
CA2926304C (en) | Use of a reagent for the lysis of erythrocytes as well as methods and kits relating thereto | |
CN104830830A (en) | A blood anticoagulant used for protecting free DNA and applications thereof | |
US20230157274A1 (en) | Nucleic acid and cell preservative compositions and methods of use | |
CN110616218B (en) | Blood RNA preservation solution and preparation method thereof, blood RNA preservation tube and preservation extraction method | |
CN117546837A (en) | Blood preservation solution suitable for NK cell culture and preparation method and application thereof | |
WO2024054494A1 (en) | Preservative composition for biological markers and biological samples and methods of use | |
EP3989722A1 (en) | Compositions for the stabilization of cell-free nucleic acids and methods thereof | |
CN111850095A (en) | Novel preservation solution for microbial nucleic acid in urine | |
JP2020535789A (en) | Cell-free nucleic acids and methods and compositions for stabilizing cells | |
CN108094407A (en) | A kind of preparation method of cell-preservation liquid and Phlegm Cells reference material | |
KR102002643B1 (en) | Method of diagnosing rejection after transplantation | |
EP4317454A1 (en) | Method for detecting microrna in biological sample, composition of hydrochloride of neutral amino acid, and container | |
Hackstein et al. | HUMAN MONOCYTES REPRESENT A COMPETITIVE SOURCE OF INTERFERON-ALPHA IN PERIPHERAL BLOOD: 1515 | |
Chen et al. | EXPRESSION OF ARGINASE 1 (ARG1), THE ALTERNATIVE ACTIVATED MACROPHAGES MARKER IN RAT MODEL OF CARDIAC TRANSPLANTATION: 1514 | |
Karczewski et al. | ROLE OF TH1/TH2 CYTOKINES IN KIDNEY ALLOGRAFT REJECTION: 1516 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20221103 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240307 |